Scholarlink

Objective <p>To describe the impact of nutrient-stimulated hormone (NuSH) therapies on weight loss by bariatric surgery type, diabetes status, and timing of initial NuSH prescription.</p> Methods <p>Retrospective study of 1638 adults who underwent bariatric surgery at a single academic medical center between 2015 and 2022. Baseline demographics, NuSH therapy prescriptions, and follow-up weights were obtained from electronic health records. We calculated percent total weight loss (%TWL) over time using linear mixed models.</p> Results <p>Patients who underwent Roux-en-Y gastric bypass (RYGB) had greater %TWL compared to those who underwent sleeve gastrectomy (SG). Those without diabetes had greater %TWL compared to those with diabetes. At 72 months, adjusted average %TWL was highest in patients who received NuSH prescriptions both before and after surgery (22.7%, 95% CI: 17.9–27.5), followed by those with prescriptions only after surgery (19.9%, 95% CI: 18.3–21.4) and those without prescriptions (19.6%, 95% CI: 18.1–21.2). The greatest %TWL was seen in patients who had prescriptions within 6 months after surgery.</p> Conclusion <p>Individuals who underwent RYGB and who did not have diabetes had the highest %TWL. Receiving a NuSH prescription both before and after surgery and early NuSH initiation were associated with the greatest %TWL.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Utilization and outcomes of nutrient-stimulated hormone therapies in patients undergoing bariatric surgery

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月20日

查看全文
  • Claudia R. Villatoro Santos,
  • Hector D. Estrada Tock,
  • Haoran Tang,
  • Laura N. McEwen,
  • Andrew Kraftson,
  • William H. Herman,
  • Amy E. Rothberg

摘要

Objective

To describe the impact of nutrient-stimulated hormone (NuSH) therapies on weight loss by bariatric surgery type, diabetes status, and timing of initial NuSH prescription.

Methods

Retrospective study of 1638 adults who underwent bariatric surgery at a single academic medical center between 2015 and 2022. Baseline demographics, NuSH therapy prescriptions, and follow-up weights were obtained from electronic health records. We calculated percent total weight loss (%TWL) over time using linear mixed models.

Results

Patients who underwent Roux-en-Y gastric bypass (RYGB) had greater %TWL compared to those who underwent sleeve gastrectomy (SG). Those without diabetes had greater %TWL compared to those with diabetes. At 72 months, adjusted average %TWL was highest in patients who received NuSH prescriptions both before and after surgery (22.7%, 95% CI: 17.9–27.5), followed by those with prescriptions only after surgery (19.9%, 95% CI: 18.3–21.4) and those without prescriptions (19.6%, 95% CI: 18.1–21.2). The greatest %TWL was seen in patients who had prescriptions within 6 months after surgery.

Conclusion

Individuals who underwent RYGB and who did not have diabetes had the highest %TWL. Receiving a NuSH prescription both before and after surgery and early NuSH initiation were associated with the greatest %TWL.